 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | 20–30% |
| Metabolism | Hepatic |
| Eliminationhalf-life | 8.6 hours |
| Excretion | Mostlyrenal, also biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.067.807 |
| Chemical and physical data | |
| Formula | C17H20FN3O3 |
| Molar mass | 333.363 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pefloxacin is aquinolone antibiotic used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.
Pefloxacin was developed in 1979 and approved in France for human use in 1985.[1]
Pefloxacin has been increasingly used as a veterinary medicine to treat microbial infections.[4]
Pefloxacin is abroad-spectrum antibiotic that is active against bothGram-positive andGram-negative bacteria. It functions by inhibitingDNA gyrase, a type IItopoisomerase, and topoisomerase IV,[5] which is an enzyme necessary to separate, replicated DNA, thereby inhibiting cell division.
Tendinitis and rupture, usually of the Achilles tendon, are class-effects of the fluoroquinolones, most frequently reported with pefloxacin.[6] The estimated risk of tendon damage during pefloxacin therapy has been estimated by the French authorities in 2000 to be 1 case per 23,130 treatment days as compared to ciprofloxacin where it has been estimated to be 1 case per 779,600.[7]
